BPMC
Price
$72.05
Change
+$2.41 (+3.46%)
Updated
Dec 1, 6:59 PM EST
74 days until earnings call
NTLA
Price
$30.84
Change
+$1.21 (+4.08%)
Updated
Dec 1, 6:59 PM EST
81 days until earnings call
Ad is loading...

Analysis and predictions BPMC vs NTLA

Header iconBPMC vs NTLA Comparison
Open Charts BPMC vs NTLABanner chart's image
Blueprint Medicines
Price$72.05
Change+$2.41 (+3.46%)
Volume$358.49K
CapitalizationN/A
Intellia Therapeutics
Price$30.84
Change+$1.21 (+4.08%)
Volume$843.87K
CapitalizationN/A
View a ticker or compare two or three
BPMC vs NTLA Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
BPMC vs. NTLA commentary
Dec 04, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BPMC is a Buy and NTLA is a Buy.

COMPARISON
Comparison
Dec 04, 2023
Stock price -- (BPMC: $72.05 vs. NTLA: $30.84)
Brand notoriety: BPMC and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BPMC: 118% vs. NTLA: 111%
Market capitalization -- BPMC: $4.2B vs. NTLA: $2.74B
BPMC [@Biotechnology] is valued at $4.2B. NTLA’s [@Biotechnology] market capitalization is $2.74B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BPMC’s FA Score shows that 0 FA rating(s) are green whileNTLA’s FA Score has 0 green FA rating(s).

  • BPMC’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 0 green, 5 red.
According to our system of comparison, BPMC is a better buy in the long-term than NTLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BPMC’s TA Score shows that 7 TA indicator(s) are bullish while NTLA’s TA Score has 7 bullish TA indicator(s).

  • BPMC’s TA Score: 7 bullish, 4 bearish.
  • NTLA’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than BPMC.

Price Growth

BPMC (@Biotechnology) experienced а +5.26% price change this week, while NTLA (@Biotechnology) price change was -0.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.15%. For the same industry, the average monthly price growth was +30.64%, and the average quarterly price growth was +27.15%.

Reported Earning Dates

BPMC is expected to report earnings on Feb 15, 2024.

NTLA is expected to report earnings on Feb 22, 2024.

Industries' Descriptions

@Biotechnology (+3.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for BPMC with price predictions.
OPEN
A.I.dvisor published
a Summary for NTLA with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
BPMC($4.2B) has a higher market cap than NTLA($2.75B). BPMC YTD gains are higher at: 64.460 vs. NTLA (-11.608). NTLA (-476.94M) and BPMC (-486.66M) have comparable annual earnings (EBITDA) . NTLA has more cash in the bank: 855M vs. BPMC (713M). NTLA has less debt than BPMC: NTLA (118M) vs BPMC (334M). BPMC has higher revenues than NTLA: BPMC (216M) vs NTLA (51.8M).
BPMCNTLABPMC / NTLA
Capitalization4.2B2.75B153%
EBITDA-486.66M-476.94M102%
Gain YTD64.460-11.608-555%
P/E Ratio17.70N/A-
Revenue216M51.8M417%
Total Cash713M855M83%
Total Debt334M118M283%
FUNDAMENTALS RATINGS
BPMC vs NTLA: Fundamental Ratings
BPMC
NTLA
OUTLOOK RATING
1..100
4311
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
51
Fair valued
PROFIT vs RISK RATING
1..100
9288
SMR RATING
1..100
9996
PRICE GROWTH RATING
1..100
3659
P/E GROWTH RATING
1..100
58100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (51) in the Biotechnology industry is in the same range as BPMC (82). This means that NTLA’s stock grew similarly to BPMC’s over the last 12 months.

NTLA's Profit vs Risk Rating (88) in the Biotechnology industry is in the same range as BPMC (92). This means that NTLA’s stock grew similarly to BPMC’s over the last 12 months.

NTLA's SMR Rating (96) in the Biotechnology industry is in the same range as BPMC (99). This means that NTLA’s stock grew similarly to BPMC’s over the last 12 months.

BPMC's Price Growth Rating (36) in the Biotechnology industry is in the same range as NTLA (59). This means that BPMC’s stock grew similarly to NTLA’s over the last 12 months.

BPMC's P/E Growth Rating (58) in the Biotechnology industry is somewhat better than the same rating for NTLA (100). This means that BPMC’s stock grew somewhat faster than NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BPMCNTLA
RSI
ODDS (%)
Bearish Trend 3 days ago
71%
Bullish Trend 3 days ago
70%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
74%
Bearish Trend 3 days ago
78%
Momentum
ODDS (%)
Bullish Trend 6 days ago
83%
Bullish Trend 3 days ago
84%
MACD
ODDS (%)
Bullish Trend 6 days ago
85%
Bullish Trend 3 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
80%
Advances
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 5 days ago
77%
Declines
ODDS (%)
Bearish Trend 18 days ago
76%
Bearish Trend 21 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
73%
Bullish Trend 7 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
69%
Bearish Trend 3 days ago
88%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
DEEP33.710.85
+2.59%
Roundhill Acquirers Deep Value ETF
LEO5.780.08
+1.40%
BNY Mellon Strategic Municipals
DIM58.940.64
+1.10%
WisdomTree International MidCap Div ETF
DIP25.250.26
+1.03%
BTD Capital Fund
FLRN30.590.03
+0.10%
SPDR® Blmbg Inv Grd Flt Rt ETF

BPMC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BPMC has been loosely correlated with MDGL. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if BPMC jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BPMC
1D Price
Change %
BPMC100%
+3.46%
MDGL - BPMC
50%
Loosely correlated
+4.83%
NTLA - BPMC
49%
Loosely correlated
+4.08%
AGIO - BPMC
48%
Loosely correlated
+3.01%
RARE - BPMC
45%
Loosely correlated
+3.37%
ORMP - BPMC
44%
Loosely correlated
-4.05%
More